Brief: Sandoz Group Signs Global Collaboration Agreement With Henlius

Sandoz AG

29/04/2025 16:02

April 29 (Reuters) - SANDOZ GROUP AG SDZ.S:

SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS

SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS

AGREEMENT VALUED AT UP TO USD 301 MILLION

CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU

TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB

AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION

Source text: ID:nGNE8k7F37

Further company coverage: SDZ.S

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))